ImCheck Therapeutics SAS announced that it has raised €96 million in an equity round of funding co-led by new investors, Earlybird Venture Capital GmbH & Co. KG and Andera Partners on June 13, 2022. The transaction also included participation from new investors,The Invus Group, LLC and The Leukemia & Lymphoma Society, Inc. Therapy Acceleration Program, returning investors, Kurma Growth Opportunities Fund, a fund managed by Kurma Partners SA, Eurazeo Investment Manager, GIMV NV, EQT Life Sciences, Boehringer Ingelheim Venture Fund L.P., a fund managed by Boehringer Ingelheim, Investment Arm, Pfizer Venture Investments LLC, Large Venture Fund and InnoBio 2, FCPI, funds managed by Bpifrance Investissement SAS, Wellington Partners Advisory AG, Agent Capital, LLC, Pureos Bioventures and Alexandria Venture Investments, LLC.

As a part of the transaction, Florent Gros of Earlybird Venture Capital GmbH & Co. KG and Raphaël Wisniewski of Andera Partners will join the company's board. The last outstanding tranche of previous round is converted into series C shares for €16 million in this round of funding.

The round is upsized.